Replies to post #4 on Barr Pharmaceuticals Inc. (BRL)

[DewDiligence]

>Based on Barr's 108.1 million shares outstanding at April 28, the deal is valued at $7.19 billion before assumed debt. In a statement, the companies valued the deal at $7.46 billion before debt.<

The discrepancy stems from BRL’s employee stock options that become in-the-money at the buyout price.